65,437 trials
Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 9.3; 10.1 Months
Alcoholism
Primary: Alcohol Craving Rating in Response to Saline Infusion — 1.704; 1.766 Units on a scale
Elective Laparoscopic Surgery
Primary: Cost of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevoflurane, Total Intravenous Anesthesia (TIVA) With Propofol, or Intravenous Induction With Propofol…
Iliac Artery Stenosis
Primary: Device- and/or Procedure-related Major Adverse Events (MAE) — 3.4 percentage of participants — p=<0.0001
Hypertension
Primary: Change in Diastolic Blood Pressure From Baseline at Week 24 — -15.3; -18.3 mmHg
Chronic Angina
Primary: Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and…
Cholelithiasis · Ultrasonography · Laparoscopic Gastric Bypass
Primary: Cholelithiasis on Transabdominal Ultrasound Versus Laparoscopic Ultrasound. — 61; 60 participants — p=0.763
Vancomycin Resistance Enterococcus Faecium
Primary: Number of Participants With Adverse Drug Reactions. — 10; 3; 3; 1 participants
Sarcopenia
Primary: Change From Baseline in Participant Lean Body Mass — 1.26; 0.29 kg
Constipation-predominant Irritable Bowel Syndrome
Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale
Staphylococcal Infections
Primary: Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert. — 1; 1; 1; 1 participants
Healthy
Primary: Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran — 1147.64; 908.48 ng*hr/mL
Lymphoma
Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…
Depression · Anxiety · Insomnia
Primary: Change in Anterior Cingulate Cortex Glutamine From Baseline to Week 1. — 0.00059; 0.00908 ratio (glutamine to creatine) — p=0.88
Increased Drug Resistance
Primary: the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment — 0.0; 10.9; -6.5; 30.5 seconds — p=0.00